Avacta Group Plc (AVCT) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to the Avacta Group Plc investor presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and could be submitted at any time via the q and a tab situated on the right hand corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review all questions submitted today and publish responses where it's appropriate to do so. Before we begin, I'd like to submit the following poll, and I'd now like to hand you over to the management team. Christina, good afternoon. Good afternoon. Thank you very much coming to you from London, and a very good morning to our colleagues joining from The United States. We're thrilled today to bring you our fiscal year twenty twenty five preliminary results and a short business update. Let me start first on the research and development side for our company. The Avacta vision and our strategy, our vision is to conquer cancer with existing therapies while preserving patient vitality and improve healing. You've heard us say that in a world where effective cancer therapy often means a difficult trade off between efficacy and safety, our precision platform has the potential to offer something very different, hope without compromise. The strategy for Avacta is to develop and ultimately to commercialize a broad portfolio of drugs, given that, importantly, FAP, or the enzyme that our platform is based on, is expressed in ninety percent of solid tumors, which represents a very large market opportunity for our precision technology. Our technology is capable of repurposing a range of oncology drugs to significantly reduce toxicity by ...